COI.
close Submit Innovation
close
Manufacturing verified Verified Outcome TRL 9

Manufacturing ‘Lean Digital’ Transformation

domain Client: A global pharmaceutical manufacturer handshake Provider: Tulip Interfaces schedule Deploy: 2023
85 Impact
Enterprise Ready
Evidence Score: A/10
Strength: High

Executive Summary

ANALYST: COI RESEARCH

Democratization of shop-floor app development to digitized paper processes and integrate IoT devices.

rate_review Analyst Verdict

"Medium Risk (Governance). 'Shadow IT' risk is mitigated by a strong centralized validation model. Efficiency gains directly increase asset utilization."

lock
Full Audit Report Available Includes Risk Register, Technical Specs & Compliance Data.

warning The Challenge

Paper-based 'Lean' initiatives had stalled. Legacy MES systems were rigid and expensive to modify, preventing frontline engineers from adapting workflows to improve efficiency.

psychology The Solution

Adopted a No-Code platform (Tulip) enabling engineers to build digital logbooks and IoT-integrated apps. Established a 'Tulip Exploitation Network' to validate and template successful apps globally.

settings_suggest Technical & Deployment Specs

Integrations
IoT Devices
Deployment Model
SaaS / Edge
Data Classification
Operational
Estimated TCO / ROI
Low (vs Legacy MES)
POC Summary ( to )

"N/A"

shield Risk Register & Mitigation

Risk Factor Severity Mitigation Strategy
Shadow IT / GxP Validation Medium Centralized validation center

trending_up Impact Trajectory

Audited value realization curve

Scaled to 120 lines at 17 sites in <3 months Verified Outcome
Primary KPI29% reduction in line changeover time
Audit CycleReduced process variability by 50%

policy Compliance & Gov

  • Standards: GMP / GxP
  • Maturity (TRL): 9
  • Evidence Score: A/10
  • Data Class: Operational

folder_shared Verified Assets

description
Verified Case Study
PDF • Version 1
lock
verified_user
Technical Audit
PDF • Audited
lock
Security Architecture

The "Blind Verification" Protocol

How we verified these outcomes for A global pharmaceutical manufacturer without exposing sensitive IP or identities.

Private
lock_person

1. Raw Evidence

Audit ID: #PRIV-468
Evidence: Direct SQL Logs
Public
public

2. Verified Asset

Outcome: Verified
Ref ID: #COI-468

Strategic Action Center

Identify your current stage and take the next step.

rocket_launch
Replicate This Success
Want similar results? Request a deployment consultation.
psychology_alt
Submit Challenge
Have a different problem? Submit your problem statement.
publish
Publish Case Study
Submit your own verified evidence.
thumb_up
Verify Impact
Audit your existing solution.